<!DOCTYPE html>
<html lang="en">
   <head>
      <meta charset="utf-8">
      <title>Research</title>
      <meta name="viewport" content="width=device-width, initial-scale=1.0">
      <meta name="description" content="Hematopoiesis Research Lab, Home, University of Pittsburgh">
      <meta name="author" content="">
      <!-- Le styles -->
      <link href="css/bootstrap.min.css" rel="stylesheet">
      <link href="css/bootstrap-responsive.min.css" rel="stylesheet">
      <link href="css/theme.css" rel="stylesheet">
   </head>
   <body>
      <div class="container">
         <header class="jumbotron subhead" id="overview">
            <p class="lead">University of Pittsburgh</p>
            <h1>Hematopoiesis Research Lab</h1>
         </header>
         <div class="masthead">
            <div class="navbar">
               <div class="navbar-inner">
                  <div class="container">
                     <ul class="nav">
                        <li><a href="index.html">Home</a></li>
                        <li><a href="people.html">People</a></li>
                        <li class="active"><a href="#">Research</a></li>
                        <li><a href="publications.html">Publications</a></li>
                        <li><a href="gallery.html">Gallery</a></li>
                        <li><a href="news.html">News</a></li>
                        <li><a href="opening.html">Opening</a></li>
                        <li><a href="contact.html">Contact</a></li>
                     </ul>
                  </div>
               </div>
            </div>
         </div>
         <hr>
         <div class="row-fluid">
            <div class="span3 bs-docs-sidebar" id="navparent">
               <ul class="nav nav-list bs-docs-sidenav" data-spy="affix" data-offset-top="200" data-offset-bottom="260">
                  <li><a href="#statemet"> Overview </a></li>
                  <li><a href="#Facilisis"> Hematopoietic stem cell (HSC) and bone marrow (BM) niche interaction</a></li>
                  <li><a class="subhead" href="#Volutpat"> Description </a></li>
                  <li><a class="subhead" href="#FacilisisMagna"> Related Publications </a></li>
                  <li><a href="#Facilisis"> HSC regeneration in response to DNA damage and aging</a></li>
                  <li><a class="subhead" href="#Volutpat"> Description </a></li>
                  <li><a class="subhead" href="#FacilisisMagna"> Related Publications </a></li>
                  <li><a href="#Facilisis"> Interplay between DNA damage and immune response in leukemogenesis</a></li>
                  <li><a class="subhead" href="#Volutpat"> Description </a></li>
                  <li><a class="subhead" href="#FacilisisMagna"> Related Publications </a></li>
                  <li><a href="#Facilisis"> The role of Fanconi Anemia (FA) proteins in hematopoiesis</a></li>
                  <li><a class="subhead" href="#Volutpat"> Description </a></li>
                  <li><a class="subhead" href="#FacilisisMagna"> Related Publications </a></li>
               </ul>
            </div>
            <div class="span8 offset1">
               <section id="statemet">
                  <div class="page-header">
                     <h3>Overview</h3>
                     <hr>
                     <p>Dr. Du's research is centered on pathophysiology of hematologic diseases such as bone marrow (BM) failure and leukemia. Dr. Du has a broad background in hematopoiesis, stem cell biology & aging, cellular metabolism and tumor microenvironment, with specific training and expertise in DNA damage response/repair, mouse modeling, metabolite profiling, and in vivo disease modeling. She has been investigating the mechanism of hematopoietic stem cell (HSC) mobilization and BM niche engraftment as well as the factors implicated in cell proliferation and apoptosis. She has identified functional interactions between certain factors implicated in cell polarity, adhesion/migration, stem cell metabolism and aging. These studies led to numerous peer-reviewed scientific papers in high-impact scientific journals, including Blood, JCI, Nat Communications, Leukemia and so on. Her current research interests include: 1) Define the molecular and functional collaboration between a major cell signaling (FA) pathway and immunometabolic regulation in HSCs; 2) Target stem cell-niche interaction for improved therapy for patients with bone marrow failure and leukemia; 3) Study a novel interplay between DDR and immune responses in FA leukemogenesis; 4) Study on the systemic immune effects of persistent DNA damage using mouse and human models of DNA repair deficiency and aging; and 5) Mechanistic and functional elucidation of the role of a novel paracrine Wnt5a-Prox1 signaling axis in regulating HSC regeneration under conditions of injury and aging.
                     </p>
                  </div>
               </section>
               <section id="Facilisis">
                  <div class="page-header">
                     <h3>Hematopoietic stem cell (HSC) and bone marrow (BM) niche interaction</h3>
                  </div>
                  <div class="row-fluid">
                     <div class="span12">
                        <section id="Description">
                           <h4>Description</h4>
                           <br/>
                           <img src="images/solar-2.jpg" class="float-right" alt="Description"/>
                           <p>
                              The project aims to investigate a previously unknown crosstalk between DNA damage and immune responses in Fanconi anemia (FA) leukemogenesis. Defining the molecular and functional collaboration between diminished DNA damage response resulted from FA deficiency and dysregulated immune response in the context of leukemia development will open up a new avenue of research designed to target these interacting pathways for developing innovative therapeutic strategies for FA and other leukemia.. 
                           </p>
                           <p>
                              My laboratory focuses on elucidating the mechanisms by which the Fanconi anemia (FA) proteins regulate hematopoietic stem cells in the context of bone marrow failure (BMF) and leukemia development. The goal of my research is to identify novel pharmaceutical targets for the treatment of patients with FA and other bone marrow failure syndromes (BMFS).
                           </p>
                       The process of FA disease progression in the context of hematopoiesis is characterized by bone marrow failure, clonal proliferation of hematopoietic stem (HSC) and progenitor (P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The only curable treatment for this devastating disease is stem cell therapy through bone marrow transplantation.
                           </p></section>
                        <hr>
                           <section id="Related publications">
                           <h4>Related publications</h4>
                           <br/>
                           <ol class="resources">
                              <li>Du W, Erden O, Wilson A, Sipple J, Schick J, Mehta P, Myers KC, Davies SM, Steinbrecher K, Pang Q. (2014) Deletion of Fanca or Fancd2 dysregulates Treg in mice. Blood. 123(12):1938-1947.
                              </li>
                              <li>Du W, Rani R, Sipple J, Schick J, Myer KC, Mehta P, Davies SM, Pang Q. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 119(18):4142-4151.  
                              </li>
                              <li>Du W, Li X, Sipple J, Pang Q. (2011) Overexpression of IL-3RÔÅ° on CD34+CD38- stem cells defines leukemia-initiating cells in FA AML. Blood. 117(16):4243-4252. 
                              </li>
                              <li>Li J, Du W, Pike S, Andreassen PR, Pang Q. (2009) Oxidative-stress specific interaction between FANCD2 and FOXO3a. Blood. 115(80):1545-1548.
                              </li>
                           </ol>
                        </section>
               <section id="Facilisis">
                  <div class="page-header">
                     <h3>HSC regeneration in response to DNA damage and aging</h3>
                  </div>
                  <div class="row-fluid">
                     <div class="span12">
                        <section id="Description">
                           <h4>Description</h4>
                           <br/>
                           <img src="images/solar-2.jpg" class="float-right" alt="Description"/>
                           <p>
                              The project aims to investigate a previously unknown crosstalk between DNA damage and immune responses in Fanconi anemia (FA) leukemogenesis. Defining the molecular and functional collaboration between diminished DNA damage response resulted from FA deficiency and dysregulated immune response in the context of leukemia development will open up a new avenue of research designed to target these interacting pathways for developing innovative therapeutic strategies for FA and other leukemia.. 
                           </p>
                           <p>
                              My laboratory focuses on elucidating the mechanisms by which the Fanconi anemia (FA) proteins regulate hematopoietic stem cells in the context of bone marrow failure (BMF) and leukemia development. The goal of my research is to identify novel pharmaceutical targets for the treatment of patients with FA and other bone marrow failure syndromes (BMFS).
                           </p>
                       The process of FA disease progression in the context of hematopoiesis is characterized by bone marrow failure, clonal proliferation of hematopoietic stem (HSC) and progenitor (P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The only curable treatment for this devastating disease is stem cell therapy through bone marrow transplantation.
                           </p></section>
                        <hr>
                           <section id="Related publications">
                           <h4>Related publications</h4>
                           <br/>
                           <ol class="resources">
                              <li>Du W, Erden O, Wilson A, Sipple J, Schick J, Mehta P, Myers KC, Davies SM, Steinbrecher K, Pang Q. (2014) Deletion of Fanca or Fancd2 dysregulates Treg in mice. Blood. 123(12):1938-1947.
                              </li>
                              <li>Du W, Rani R, Sipple J, Schick J, Myer KC, Mehta P, Davies SM, Pang Q. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 119(18):4142-4151.  
                              </li>
                              <li>Du W, Li X, Sipple J, Pang Q. (2011) Overexpression of IL-3RÔÅ° on CD34+CD38- stem cells defines leukemia-initiating cells in FA AML. Blood. 117(16):4243-4252. 
                              </li>
                              <li>Li J, Du W, Pike S, Andreassen PR, Pang Q. (2009) Oxidative-stress specific interaction between FANCD2 and FOXO3a. Blood. 115(80):1545-1548.
                              </li>
                           </ol>
                        </section>
                        <section id="Facilisis">
                  <div class="page-header">
                     <h3>Hematopoietic stem cell (HSC) and bone marrow (BM) niche interaction</h3>
                  </div>
                  <div class="row-fluid">
                     <div class="span12">
                        <section id="Description">
                           <h4>Description</h4>
                           <br/>
                           <img src="images/solar-2.jpg" class="float-right" alt="Description"/>
                           <p>
                              The project aims to investigate a previously unknown crosstalk between DNA damage and immune responses in Fanconi anemia (FA) leukemogenesis. Defining the molecular and functional collaboration between diminished DNA damage response resulted from FA deficiency and dysregulated immune response in the context of leukemia development will open up a new avenue of research designed to target these interacting pathways for developing innovative therapeutic strategies for FA and other leukemia.. 
                           </p>
                           <p>
                              My laboratory focuses on elucidating the mechanisms by which the Fanconi anemia (FA) proteins regulate hematopoietic stem cells in the context of bone marrow failure (BMF) and leukemia development. The goal of my research is to identify novel pharmaceutical targets for the treatment of patients with FA and other bone marrow failure syndromes (BMFS).
                           </p>
                       The process of FA disease progression in the context of hematopoiesis is characterized by bone marrow failure, clonal proliferation of hematopoietic stem (HSC) and progenitor (P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The only curable treatment for this devastating disease is stem cell therapy through bone marrow transplantation.
                           </p></section>
                        <hr>
                           <section id="Related publications">
                           <h4>Related publications</h4>
                           <br/>
                           <ol class="resources">
                              <li>Du W, Erden O, Wilson A, Sipple J, Schick J, Mehta P, Myers KC, Davies SM, Steinbrecher K, Pang Q. (2014) Deletion of Fanca or Fancd2 dysregulates Treg in mice. Blood. 123(12):1938-1947.
                              </li>
                              <li>Du W, Rani R, Sipple J, Schick J, Myer KC, Mehta P, Davies SM, Pang Q. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 119(18):4142-4151.  
                              </li>
                              <li>Du W, Li X, Sipple J, Pang Q. (2011) Overexpression of IL-3RÔÅ° on CD34+CD38- stem cells defines leukemia-initiating cells in FA AML. Blood. 117(16):4243-4252. 
                              </li>
                              <li>Li J, Du W, Pike S, Andreassen PR, Pang Q. (2009) Oxidative-stress specific interaction between FANCD2 and FOXO3a. Blood. 115(80):1545-1548.
                              </li>
                           </ol>
                        </section>
               <section id="Facilisis">
                  <div class="page-header">
                     <h3>Interplay between DNA damage and immune response in leukemogenesis</h3>
                  </div>
                  <div class="row-fluid">
                     <div class="span12">
                        <section id="Description">
                           <h4>Description</h4>
                           <br/>
                           <img src="images/solar-2.jpg" class="float-right" alt="Description"/>
                           <p>
                              The project aims to investigate a previously unknown crosstalk between DNA damage and immune responses in Fanconi anemia (FA) leukemogenesis. Defining the molecular and functional collaboration between diminished DNA damage response resulted from FA deficiency and dysregulated immune response in the context of leukemia development will open up a new avenue of research designed to target these interacting pathways for developing innovative therapeutic strategies for FA and other leukemia.. 
                           </p>
                           <p>
                              My laboratory focuses on elucidating the mechanisms by which the Fanconi anemia (FA) proteins regulate hematopoietic stem cells in the context of bone marrow failure (BMF) and leukemia development. The goal of my research is to identify novel pharmaceutical targets for the treatment of patients with FA and other bone marrow failure syndromes (BMFS).
                           </p>
                       The process of FA disease progression in the context of hematopoiesis is characterized by bone marrow failure, clonal proliferation of hematopoietic stem (HSC) and progenitor (P) cells, and progression to myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). The only curable treatment for this devastating disease is stem cell therapy through bone marrow transplantation.
                           </p></section>
                        <hr>
                           <section id="Related publications">
                           <h4>Related publications</h4>
                           <br/>
                           <ol class="resources">
                              <li>Du W, Erden O, Wilson A, Sipple J, Schick J, Mehta P, Myers KC, Davies SM, Steinbrecher K, Pang Q. (2014) Deletion of Fanca or Fancd2 dysregulates Treg in mice. Blood. 123(12):1938-1947.
                              </li>
                              <li>Du W, Rani R, Sipple J, Schick J, Myer KC, Mehta P, Davies SM, Pang Q. (2012) The FA pathway counteracts oxidative stress through selective protection of antioxidant defense gene promoters. Blood. 119(18):4142-4151.  
                              </li>
                              <li>Du W, Li X, Sipple J, Pang Q. (2011) Overexpression of IL-3RÔÅ° on CD34+CD38- stem cells defines leukemia-initiating cells in FA AML. Blood. 117(16):4243-4252. 
                              </li>
                              <li>Li J, Du W, Pike S, Andreassen PR, Pang Q. (2009) Oxidative-stress specific interaction between FANCD2 and FOXO3a. Blood. 115(80):1545-1548.
                              </li>
                           </ol>
                        </section>
                     </div>
                  </div>
               </section>
               <hr>
            </div>
         </div>
      </div>
      <footer id="footer">
         <div class="container-fluid">
            <div class="row-fluid">
               <div class="span5">
                  <h3>Contact Information</h3>
                  <p><b>Office Hours: </b>Monday-Friday (8.00am - 5.00pm)</p>
                  <p><b>Phone: </b>412-623-2211</p>
               
                  <a href="mailto:duw@upmc.edu">Email</a>
               </div>
               <div class="span2">
                  <a href="https://mybrandnewlogo.com/"><img src = "thumbs/generic-logo.JPG" alt="research-lab-logo"/></a>
               </div>
               <div class="span5">
                  <h3>Address</h3>
                  <p>Hematopoiesis Research Laboratory<br>
                     5117 Center Avenue<br>
                     Pittsburgh, PA<br>
                     USA 15213
                  </p>
                  <a href="http://maps.google.com/">Show Map</a>
               </div>
            </div>
         </div>
      </footer>

      <!-- Le javascript
         ================================================== -->
      <!-- Placed at the end of the document so the pages load faster -->
      <script src="js/jquery-1.9.1.min.js"></script>
      <script src="js/bootstrap.min.js"></script>
      <script>
         $(document).ready(function() {
             $(document.body).scrollspy({
                 target: "#navparent"
             });
         });
         
      </script>
   </body>
</html>
